Market Place
Ipca Laboratories finished dosage facilities at Silvasa and
Pithampur (India) were put on the FDA Import Alert List this week, an outcome
of Ipca running into problems in yet another FDA inspection. The latest alert
comes after Ipca’s API facility in Ratlam (India) was banned from exporting to the
U.S. in January this year. However, when reviewing the details of Ipca’s alert,
is there a business opportunity which
can be capitalized upon?
The FDA Import Alert, while banning all imports from the Pithampur facility, has stopped everything coming out of the Silvasa plant except Hydroxychloroquine Sulfate & Propranolol Hydrochloride. Ipca’s Ratlam facility had received a similar exemption earlier for the following APIs: Sulfamethoxazole, Trimethoprim, Ondansetron, Hydroxychloroquine Sulfate, Propranolol Hydrochloride and Furosemide. Given all the details that have been published about the observations at Ipca’s various facilities, a complete shutdown of all imports into the U.S. would
have been expected.
Why did a few of Ipca’s products get an FDA import alert exemption?
Business Standard reported, at the time of covering the initial Ratlam ban that “Given the acute shortage in the US, the
FDA, however, has exempted four APIs from the import ban.” The article also mentions the market growth of Hydroxychloroquine from $30 million to $120 million in the last few years. While the FDA hasn’t yet put Hydroxychloroquine on their drug shortage list, concerns regarding supply
disruption are already being felt.
Wyeth’s branded Propranolol Hydrochloride was a $215 million product in 2006, before intense generic competition reduced the market to about 10% of its original size in less than two years. While almost every major generic company has some variant of Propranolol Hydrochloride on the market, the number of API suppliers are extremely limited. Pharma Compass’ database shows that
as Ipca, Albemarle (USA) and Cosmo Spa (Italy) are the only active Drug Master
Files in the FDA database, capacity expansion constraints in Europe and United
States could provide an opportunity for compliant API manufacturing of
Propranolol Hydrochloride.
With API manufacturers looking for new horizons, Ipca’s exemptions of old products like Sulfamethoxazole, Trimethoprim, Ondansetron, Hydroxychloroquine
Sulfate, Propranolol Hydrochloride and Furosemide should provide an manufacturing
and marketing opportunity worth examining.
Search our database for Sulfamethoxazole, Trimethoprim, Ondansetron, Hydroxychloroquine
Sulfate, Propranolol
Hydrochloride and Furosemide
to study the competitive landscape of manufacturers, pricing information and a
lot more.
Impressions: 4264
https://www.pharmacompass.com/radio-compass-blog/the-silver-lining-in-ipca-s-import-alert-blues
#PharmaFlow by PHARMACOMPASS
27 Mar 2015
Share
